Injectable opioid agonist treatment: An evolutionary concept analysis
- PMID: 33993526
- DOI: 10.1002/nur.22140
Injectable opioid agonist treatment: An evolutionary concept analysis
Abstract
Canada is currently in the midst of an overdose crisis. With new and innovative approaches desperately needed, injectable opioid agonist treatment (iOAT) should be considered as an integral treatment option to prevent even more fatalities. These programs provide injectable diacetylmorphine or hydromorphone to clients with severe opioid use disorders. Currently, they remain an under-executed and under-studied treatment modality. To better understand why this may be, we performed an evolutionary concept analysis as described by Rodgers. The attributes, antecedents, consequences, and surrogate terms of iOAT were unpacked and explored. Further, four themes were identified within the literature: (1) physical and mental health, (2) illicit drug use, (3) criminal behavior, and (4) ethical considerations. Recommendations surrounding the need for additional studies that focus on the perspectives of people who use opioids (PWUO), the necessity of nursing advocacy in iOAT, and the consideration of a changing illicit drug supply were explored. Further, theoretical analysis coupled with direct input from PWUO was discussed as a necessity to move forward with iOAT.
Keywords: harm reduction; heroin-assisted therapy; injectable opioid agonist treatment; opioid use disorder; overdose crisis; safer supply; substance use.
© 2021 Wiley Periodicals LLC.
Similar articles
-
Challenges for the implementation of injectable opioid agonist treatment: a scoping review.Harm Reduct J. 2024 Dec 4;21(1):217. doi: 10.1186/s12954-024-01102-x. Harm Reduct J. 2024. PMID: 39633369 Free PMC article.
-
Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.CMAJ Open. 2021 Feb 23;9(1):E115-E124. doi: 10.9778/cmajo.20200021. Print 2021 Jan-Mar. CMAJ Open. 2021. PMID: 33622764 Free PMC article.
-
Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).Int J Drug Policy. 2023 Feb;112:103948. doi: 10.1016/j.drugpo.2022.103948. Epub 2022 Dec 29. Int J Drug Policy. 2023. PMID: 36586152 Review.
-
Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada.Can J Public Health. 2020 Aug;111(4):606-609. doi: 10.17269/s41997-020-00315-4. Epub 2020 Mar 27. Can J Public Health. 2020. PMID: 32221867 Free PMC article.
-
Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.Subst Abuse Treat Prev Policy. 2021 Mar 5;16(1):22. doi: 10.1186/s13011-021-00358-x. Subst Abuse Treat Prev Policy. 2021. PMID: 33673847 Free PMC article.
Cited by
-
Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.Harm Reduct J. 2023 Nov 1;20(1):162. doi: 10.1186/s12954-023-00896-6. Harm Reduct J. 2023. PMID: 37915058 Free PMC article.
-
Shaping and shifting schemas on supervised injectable opioid treatment: findings from a cross-sectional qualitative study in two German treatment facilities.Addict Sci Clin Pract. 2024 May 27;19(1):45. doi: 10.1186/s13722-024-00475-5. Addict Sci Clin Pract. 2024. PMID: 38802962 Free PMC article.
-
"It's a delicate balance": clinicians' experiences of providing heroin-assisted treatment.Harm Reduct J. 2024 Dec 31;21(1):230. doi: 10.1186/s12954-024-01135-2. Harm Reduct J. 2024. PMID: 39741328 Free PMC article.
-
'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England.Harm Reduct J. 2023 May 12;20(1):66. doi: 10.1186/s12954-023-00785-y. Harm Reduct J. 2023. PMID: 37173697 Free PMC article.
References
REFERENCES
-
- Afolabi, M. , & Sodeke, S. (2017). Reconciling competence and consent in opioid-dependence research: The value of vulnerability rhetoric. The American Journal of Bioethics, 17(12), 48-50. https://doi.org/10.1080/15265161.2017.1388871
-
- Bansback, N. , Guh, D. , Oviedo-Joekes, E. , Brissette, S. , Harrison, S. , Janmohamed, A. , Krausz, M. , MacDonald, S. , Marsh, D. C. , Schechter, M. T. , & Anis, A. H. (2018). Cost-effectiveness of hydromorphone for severe opioid use disorder: Findings from the SALOME randomized clinical trial. Addiction, 113(7), 1264-1273. https://doi.org/10.1111/add.14171
-
- Berrigan, P. (2018). A review of literature assessing public opinion of heroin assisted treatment. Heroin Addiction & Related Clinical Problems, 20(4), 13-18.
-
- Blanken, P. , Hendriks, V. , Huijsman, I. , van Ree, J. , & van Den Brink, W. (2016). Efficacy of cocaine contingency management in heroin-assisted treatment: Results of a randomized controlled trial. Drug and Alcohol Dependence, 164, 55-63. https://doi.org/10.1016/j.drugalcdep.2016.04.018
-
- Blanken, P. , Hendriks, V. , Koeter, M. , van Ree, J. , & van Den Brink, W. (2012). Craving and illicit heroin use among patients in heroin-assisted treatment. Drug and Alcohol Dependence, 120(1-3), 74-80. https://doi.org/10.1016/j.drugalcdep.2011.06.025
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical